Not Signed In -
Telmisartan and Hydrochlorothiazide |
Micardis HCT |
Clinical Trial: Hydrochlorothiazide (+) Losartan Potassium Vs. Amlodipine Comparative Study
This study is no longer recruiting patients.
|
Purpose
An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension
| Condition | Intervention | Phase |
|---|---|---|
| Essential Hypertension | Drug: MK0954A; hydrochlorothiazide (+) losartan potassium | Phase IV |
MedlinePlus related topics: High Blood Pressure
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients.
Further Study Details:
Primary Outcomes: Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipine
Secondary Outcomes: Safety/Tolerability
Expected Total Enrollment: 176
Secondary Outcomes: Safety/Tolerability
Expected Total Enrollment: 176
Study start: February 2005
Eligibility
Ages Eligible for Study: 20 Years - 75 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Patients of age 20 70 75 with essential hypertension
- SiDBP 90 ~ 114mmHg at V1 & V2
Exclusion Criteria:
- Patient has known or suspected secondary hypertension
- Patient has a history of malignant hypertension (SiSBP > 210mmHg)
- Individuals has a known sensitivity or intolerance to HCTZ or any AIIAs, or any sulfonamide-derived drugs.
- Patient has shown significant abnormal laboratory evaluations
Location Information
Korea, Republic of
MSD Korea Ltd., Seoul, 121-705, Korea, Republic of
Study chairs or principal investigators
Medical Monitor, Study Director, Merck
More Information
Study ID Numbers: 2005_067
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157963
Health Authority: Korea: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 10, 2005
Record first received: September 7, 2005
ClinicalTrials.gov Identifier: NCT00157963
Health Authority: Korea: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- Micardis HCT (Drug Digest)
- Telmisartan and Hydrochlorothiazide (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
